New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2014
10:55 EDTVSARVersartis opens at $28.00, IPO priced at $21.00
Versartis (VSAR) priced 6M shares at $21.00. Morgan Stanley and Citigroup acted as joint book running managers for the offering.
News For VSAR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 2, 2016
10:38 EDTVSARCowen says add to Versartis positions after today's data
Subscribe for More Information
07:15 EDTVSARCanaccord to hold a conference
Subscribe for More Information
07:15 EDTVSARVersartis reports confirmatory top-line two-year data from somavaratan study
Versartis announced confirmatory two-year, top-line safety and efficacy data from its ongoing Extension Study of somavaratan in children with GHD. The Extension Study is a long-term safety study that was initiated in March 2014 as patients completed the Phase 1b/2a clinical trial evaluating somavaratan therapy in treatment-naive, pre-pubertal GHD children. 57 patients were in the Extension Study during the 12-24 month period and were included in the Year 2 analyses. The Extension Study continued to show that the safety profile of somavaratan is similar to daily growth hormone therapy. Over the full 24 months of treatment, there were no drug-related serious adverse events, or SAEs, and nearly all drug-related AEs were mild and transient. Somavaratan was well tolerated and the patient discontinuation rate at 24 months was in line with expectations for long-term clinical studies.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use